Innovent Biologics

New Capabilities

Developer and marketer of tafolecimab

Innovent Biologics' tafolecimab cut LDL cholesterol by roughly 65% in a Phase 3 trial of patients who took no other lipid-lowering drug. The CREDIT-5 result is the first late-stage evidence that a Chinese-made PCSK9 antibody works as a stand-alone first-line treatment for high cholesterol.

Updated 3 days ago

New Capabilities

Developer of IBI3001

Innovent Biologics presented the first clinical data for IBI3001, an EGFR/B7H3 bispecific antibody-drug conjugate (ADC, a targeted drug carrying a chemotherapy payload), at the 2026 European Society for Medical Oncology (ESMO) congress. Of 57 patients who received the drug, 78.9% had two or more prior treatment lines. Among 53 patients evaluable for response, 30.2% responded and 88.7% had disease control.

Updated Oct 26

New Capabilities

Developer of IBI354; running two Phase 3 trials across breast and ovarian cancer

Innovent presented Phase 2 results at the European Society for Medical Oncology (ESMO) congress on October 24. The data show its experimental HER2-targeting antibody-drug conjugate (ADC), IBI354, plus pertuzumab produced a 95% confirmed response rate in patients with unresectable, locally advanced or metastatic HER2-positive breast cancer. That is 19 of 20 patients, and none developed interstitial lung disease (ILD), a lung inflammation that is a known risk with trastuzumab deruxtecan (Enhertu).

Updated Oct 26

New Capabilities

As of October 2026: Developer of SYCUME; announced positive Phase 3 results

Innovent Biologics said its drug SYCUME reduced eye protrusion in Chinese patients with inactive thyroid eye disease, meeting the primary endpoint of a Phase 3 trial. At week 24, 60.4% of treated patients hit the proptosis response threshold, versus 23.5% on placebo.

Updated Oct 12

New Capabilities

As of June 2026: Developer of arcotatug tavatecan (IBI343)

Advanced gastric cancer that returns after treatment usually kills within about six months. On June 4, 2026, Chinese biotech Innovent Biologics said its drug had slowed that clock in a late-stage trial.

Updated Jun 4